SGK1 and Obesity: Finally, pharmacological inhibition of endogenous SGK1 in this model would have provided complementary data to augment our hypothesis that SGK1 inhibition may be a novel approach to obesity-related AF, but poor bioavailability, potency, and specificity of commercially available SGK1 inhibitors currently limit their utility.